Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DTB64R
|
|||
| Drug Name |
Narsoplimab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | IgA nephropathy [ICD-11: MF8Y] | Phase 3 | [1] | |
| Thrombotic microangiopathy [ICD-11: 3B65; ICD-10: M31.1] | Phase 2 | [2] | ||
| Company |
Omeros
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mannan-binding lectin serine protease-2 (MASP2) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03608033) A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN). U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02222545) A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies. U.S.National Institutes of Health. | |||
| REF 3 | Narsoplimab, a Mannan-Binding Lectin-Associated Serine Protease-2 Inhibitor, for the Treatment of Adult Hematopoietic Stem-Cell Transplantation-Associated Thrombotic Microangiopathy. J Clin Oncol. 2022 Aug 1;40(22):2447-2457. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.